BioStock: Large shareholders about their increased holding in Chordate Medical

26 February, 2021

Last week, Chordate Medical announced that two major shareholders, Isac Brandberg AB and related parties and Jinderman & Partners AB, have increased their shareholding in the company. This is a clear sign of the two shareholders’ confidence in Chordate Medical and the company’s treatment for chronic nasal congestion and chronic migraine. BioStock contacted two representatives from Jinderman & Partners and Isac Brandberg to hear more about their expectations on Chordate Medical and why they have chosen to increase their holdings in the company.

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital.

Fler Nyheter

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate's share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of the K.O.S treatment, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Contact us

The information is handled according to our  privacy policy.